Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
7m ago MOODY : says that large share of forex loans affects Romania's banking system
7m ago SAUDI KAYAN PETROCHEMICAL : announces meeting financial conditions successfully
7m agoDJDeutsche Bank to Review Strategy Next Year
11m ago SHOKO : Tax:) (CORRECTION )
19m ago SAUDI OIL MIN : 'Let the most efficient producers produce'
24m ago UK inflation plunge does not pose deflation risk - BoE's Miles
27m ago TOWER : is Trade Me's new insurance partner
30m ago MOODY : New indirect taxes 'last resort' for GCC
37m ago BASF SE : Asset swap between BASF and Gazprom will not be completed
38m ago Saudi's Naimi says prices will stimulate demand, confident market will recover
Latest news
Advertisement
Hot News 
DENDREON : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
DIXONS CARPHONE : *exane bnp raises dixons carphone price target to 510 (450) pence - 'outperform'
BERKELEY MINERAL RESOURCES : Obsidian IR
NATURE : Warns 2014 Results To Be "Materially" Below Market View
FINISH LINE : Reports Third Quarter Fiscal Year 2015 Results
Most Read News
1d ago COMCAST : DISH, Comcast SportsNet reach deal in regional dispute
1d ago APPLE : Innovation – The Apple way
1d ago MACY : When Apple Pay Requires a Signature and When it Doesn't
1d ago INDUSTRY ANALYST JEFF KAGAN : Will AT&T GigaPower Beat Google Fiber
1d ago FRANCESCA : announces new CEO amid faltering sales
Most recommended articles
7m agoDJDeutsche Bank to Review Strategy Next Year
19m ago SAUDI OIL MIN : 'Let the most efficient producers produce'
24m ago UK inflation plunge does not pose deflation risk - BoE's Miles
37m ago Saudi's Naimi says prices will stimulate demand, confident market will recover
50m ago British upstart banks get IT boost to take on big rivals
Dynamic quotes  
ON
| OFF